Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 45

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 45
---
 common shares are granted to achieve an equivalent value relative to stock option awards. Furthermore, the compensation committee believes RSUs are an effective retention tool that maintain value even in cases where the share price is trading lower than the initial grant price. Our RSU awards generally vest in equal annual increments over a three-year period and may be subject to acceleration of vesting and exercisability under certain termination and change in control events. Vesting of equity awards is generally tied to each officer’s continuous service with us and serves as an additional retention measure. In March 2024, the compensation committee and our board of directors, as applicable, approved grants of options, with an exercise price of $6.95 per share, and RSUs to our named executive officers as set forth in the following table.

| Named Executive Officer    |     | 2024 Option Grant 
 (#)               |         |     | 2024 RSU Grant 
 (#)            |        |
| Lloyd M. Segal             |     |                   | 237,000 |     |                | 40,000 |
| Maria Koehler, M.D., Ph.D. |     |                   |  85,000 |     |                | 14,000 |
| Michael Zinda, Ph.D.       |     |                   |  85,000 |     |                | 14,000 |

The option awards vest over a four-year period, with 25% of the shares subject to the award have vested in March 2025, with the remainder of the award vesting monthly in equal installments over the following 36 months such that the award will vest in full in March 2028, subject to the executive’s continuous service with us as of each vesting date. The RSU awards vest over a three-year period, with one-thirdof the shares subject to the award vesting on the first, second and third anniversaries of March 2024, such that the award will vest in full in March 2027, subject to the executive’s continuous service with us as of each such vesting date. August 2024 Cash Retention Bonuses In light of a workforce reduction implemented in August 2024, the compensation committee and our board of directors, as applicable, approved cash retention bonuses to certain of our executive officers. Dr. Koehler and Dr. Zinda were each awarded a cash retention bonus in the amount of $115,000, to be paid over time, with the first 25% installment paid